Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operaitons (Unaudited)

v3.26.1
Condensed Consolidated Statements of Operaitons (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]        
Revenues $ 6,588,000 $ 16,742,000 $ 33,884,000 $ 49,697,000
Cost of sales 4,788,000 11,455,000 23,424,000 33,729,000
Gross profit 1,800,000 5,287,000 10,460,000 15,968,000
Operating expenses:        
Selling and administrative 4,168,000 5,717,000 12,638,000 16,817,000
Research and development 623,000 1,147,000 2,196,000 3,419,000
Total operating expenses 4,791,000 6,864,000 14,834,000 20,236,000
Operating loss (2,991,000) (1,577,000) (4,374,000) (4,268,000)
Interest expense, net (184,000) (362,000) (762,000) (1,227,000)
Net loss $ (3,175,000) $ (1,939,000) $ (5,136,000) $ (5,495,000)
Net loss per share - basic $ (0.15) $ (0.12) $ (0.27) $ (0.33)
Net loss per share - diluted $ (0.15) $ (0.12) $ (0.27) $ (0.33)
Weighted average number of common shares outstanding - basic 21,340,371 16,684,320 19,289,746 16,683,074
Weighted average number of common shares outstanding - diluted 21,340,371 16,684,320 19,289,746 16,683,074